Monday, August 30, 2021 4:04:58 PM
August 30, 2021
https://newsinvasion24.com/enzolytics-inc-otcmkts-enzc-completes-steps-necessary-for-itv-1-medication-production-and-clinical-studies-ahead-of-ema-approval/
Enzolytics Inc. (OTCMKTS: ENZC) has finalized an agreement and arrangements with Danhason and Clinic Design to advance its Anti-HIV treatment ITV—1 into clinical trials and production. These processes are necessary before the European Medicines Agency (EMA) approves a product for patient use.
Danhson to manufacturer Enzolytics’ ITV-1 treatment
The medication will be manufactured at Danhson Pharmaceutical Company facilities, and Clinic Design will undertake clinical studies. The medicines’ production is due to be completed within the next six months, with clinical trials following soon after. Pharmalex, an EU regulatory consultancy firm, will oversee the trial’s protocol.
The company announced earlier this year the formation of International Medical Partners (“IMPL”), a Limited Liability Company in Bulgaria in which it owns a 50% stake. Enzolytics will fund the initial ITV-1 therapeutic production with its partners in IMPL, funding the clinical trials and EMA licensing costs.
IMPL to supply ITV-1 therapeutics to 27 EU states
IMPL will be the sole distributor of the ITV-1 treatment in all 27 EU member nations, including Liechtenstein, Iceland, and Norway, as well as Georgia, Russia, Ukraine, Belarus, Moldova, Armenia, Azerbaijan, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Latvia, Estonia, and Lithuania. In addition, IMBL could distribute the ITV-1 treatment outside of its exclusive jurisdiction where an exclusive license is not available. The Registry Office in Sofia has received all of the papers required for IMPL registration.
CSO of Enzolytics Harry Zhabilov said, “We are excited about the progress we have made with the assistance of our IMBL partners. Contracting with Danhson, Clinic Design and PharmaLex is integral to the success of the EMA permitting process. As this is the second time our ITV-1 therapeutic has progressed through clinical trials and the first trials were successful, we are fully confident that we will succeed in the permitting process. With the reciprocal treaty between the EMA and FDA, we believe that the EMA approval with lead to further advancement of our ITV-1 as a successful therapy.”
TagsENZC ENZC News ENZC Stock Enzolytics Inc. (OTCMKTS: ENZC) OTC ENZC
You may also like
Nordic diet
HEALTH
The overwhelming Nordic diet and its importance!
August 19, 2021
CELEBRITY ENTERTAINMENT FEATURED HEALTH NEWS
Kevin Connolly revealed that he and his new born little girl were infected with Covid-19!
July 24, 2021
COVID-19 ENTERTAINMENT HEALTH NEWS
“Vaccinated ones are secured from Delta variant, masks not important,” Suggests CDC!
June 30, 2021
About the author
VIEW ALL POSTS
Avatar
Add Comment
100% natural and healthy: is it true food label!
COMMENT
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM